Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CCS1477 |
Synonyms | |
Therapy Description |
CCS1477 binds to and inhibits p300 (EP300) and CBP (CREBBP), potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (J Clin Oncol 35, 2017 (suppl; abstr 11590)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CCS1477 | CCS-1477|CCS 1477 | CBP/p300 inhibitor 13 | CCS1477 binds to and inhibits p300 (EP300) and CBP (CREBBP), potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (J Clin Oncol 35, 2017 (suppl; abstr 11590)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04068597 | Phase Ib/II | CCS1477 | Study to Evaluate CCS1477 in Haematological Malignancies | Recruiting | USA | SWE | GBR | FRA | ESP | 0 |
NCT03568656 | Phase Ib/II | Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide | Study to Evaluate CCS1477 in Advanced Tumours | Recruiting | USA | SWE | NLD | GBR | FRA | ESP | 0 |